NEW YORK, December 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Lannett Company, Inc. (NYSE: LCI), MacroGenics, Inc. (NASDAQ: MGNX), and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Karyopharm Therapeutics Inc. Research Report
On December 11, 2013, Karyopharm Therapeutics Inc. (Karyopharm) announced that the underwriters for its initial public offering of common stock have fully exercised their option to purchase an additional 1.0 million shares of common stock at the public offering price of $16.00 per share. The Company informed that it received approximately $15.2 million in proceeds from the exercise of the said option, which occurred on December 10, 2013. The Company reported that gross proceeds from the initial public offering were $125.1 million, including proceeds from the sale of the additional shares subject to the option. "With this successful fundraising, we are now in a strong position to look forward and focus on executing our clinical development strategy," said Michael Kauffman, M.D., Ph.D., CEO of Karyopharm. "The preliminary evidence of anti-tumor activity seen in Selinexor, our lead drug candidate, across multiple hematologic malignancies, as well as in solid tumors, support our plans to conduct future studies of Selinexor alone and in combination with chemotherapy and/or targeted agents." The Full Research Report on Karyopharm Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Agios Pharmaceuticals, Inc. Research Report
On December 11, 2013, Agios Pharmaceuticals, Inc. (Agios) announced an extension of one additional year to the period of exclusivity for its strategic cancer metabolism collaboration with Celgene Corporation (Celgene). Agios reported that consequent to the extension, Celgene will maintain its exclusive option to all drug candidates emerging from the Company's cancer metabolism research platform through April 2015. Agios informed that under the terms of the agreement, it will receive a $20 million payment, while Celgene will have the ability to further extend the collaboration period for one additional year on the basis of an additional payment. The Full Research Report on Agios Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Lannett Company, Inc. Research Report
On December 19, 2013, Lannett Company, Inc. (Lannett) announced that it has established a new five-year $50 million revolving credit facility with a syndicate of two lenders - Citibank, N.A., as administrative agent, and PNC Bank, National Association. The Company informed that the facility is secured by substantially all of Lannett's assets.. "This credit facility supports our plans for continued growth and provides additional capital for potential acquisitions," said Arthur Bedrosian, President and CEO of Lannett. The Full Research Report on Lannett Company, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MacroGenics, Inc. Research Report
On December 11, 2013, MacroGenics, Inc. (MacroGenics) announced the online publication of data on the isolation of cancer stem-like cells (CSLCs) from human adenosquamous carcinoma (ASC) of the lung, in the journal PLOS ONE. The Company reported that the research contributes to the expanding collection of model CSLC lines identified and characterized by MacroGenics, as well as increases the number of important models from which it can generate antibody-based drug candidates. "Our Cancer Stem-like Cell Platform provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Ongoing research at MacroGenics furthers our understanding of cancer stem cell biology and its significance in oncology treatment based on the role of these cells in tumor re-growth and metastasis." The Full Research Report on MacroGenics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ZIOPHARM Oncology, Inc. Research Report
On December 7, 2013, ZIOPHARM Oncology, Inc. (ZIOPHARM) announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. ZIOPHARM informed that the findings were presented at Melanoma Bridge 2013 Conference, held in Naples, Italy. "The ability to precisely modulate gene expression at the site of the cancer represents a potential paradigm shift in cancer treatment," said Francois Lebel, M.D., Senior Vice President of Clinical Development and Medical Operations at ZIOPHARM. "We believe the evidence of safety, efficacy and control of gene expression in this study is encouraging and warrants the completion of this trial and the pursuit of a larger Phase 2 clinical trial in patients with advanced melanoma in 2014. We look forward to reporting the full results of this study at a future medical meeting and to initiating later-stage clinical testing in a larger patient population." The Full Research Report on ZIOPHARM Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner